SEC Form 4 · accession 0001209191-17-060943
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Satlin
Officer — EVP and Chief Medical Officer
Period of report
Nov 13, 2017
Accepted (ET)
Nov 15, 2017 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.79 | Nov 13, 2017 | A | 170,500 | A | — | Nov 12, 2027 | Common Stock | 170,500 | 170,500 | D |
Explanation of responses
- F1The option vests as to one third of the shares on November 13, 2018, one third of the shares on November 13, 2019 and one third of the shares on November 13, 2020.